Nkarta Inc (Nasdaq:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, announced on Wednesday a collaboration with Columbia University Irving Medical Center for an investigator-sponsored trial (IST) of NKX019.
The trial will evaluate Nkarta's allogeneic, CD19-directed chimeric antigen receptor (CAR) NK-cell therapy in patients with systemic lupus erythematosus (SLE).
This broadens the clinical evaluation of NKX019 in lupus, complementing Nkarta's ongoing Phase 1 trial in patients with lupus nephritis (LN).
Cell therapy offers people with lupus the potential for long-term, medication-free remission.
Indivior updates on Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder
Vesper Bio announces positive Phase I results for FTD treatment
Empower Pharmacy names new president
Innovent's IBI363 receives US FDA Fast Track Designation
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Medicilon USA begins operations at second R&D centre in Massachusetts
CS Genetics names new chief operating officer and chief scientific officer
Expanse Medical names new chief executive officer and FlowPhysix board member